139 related articles for article (PubMed ID: 18436926)
1. Fetal RHD typing: Is fetal RHD typing in all RhD negative women cost effective?
Szczepura A; Bonsel G; Krauth C; Osipenko L; Haverkamp A
BMJ; 2008 Apr; 336(7650):906. PubMed ID: 18436926
[No Abstract] [Full Text] [Related]
2. Noninvasive fetal RHD genotyping to guide targeted anti-D prophylaxis-an external quality assessment workshop.
Clausen FB; Barrett AN;
Vox Sang; 2019 May; 114(4):386-393. PubMed ID: 30834546
[TBL] [Abstract][Full Text] [Related]
3. Terminating Routine Cord Blood RhD Typing of the Newborns to Guide Postnatal Anti-D Immunoglobulin Prophylaxis Based on the Results of Fetal RHD Genotyping.
Stensrud M; Bævre MS; Alm IM; Wong HY; Herud I; Jacobsen B; de Vos DDJA; Stjern HE; Sørvoll IH; Barane JB; Bagås TE; Rasmussen M; Ulvahaug N; Wamstad V; Tomter G; Akkök CA
Fetal Diagn Ther; 2023; 50(4):276-281. PubMed ID: 37379821
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive fetal RHD genotyping in the first trimester of pregnancy.
Cardo L; Prieto B; Alvarez FV
Prenat Diagn; 2012 Jan; 32(1):99. PubMed ID: 22367674
[No Abstract] [Full Text] [Related]
5. Costs and clinical outcomes of noninvasive fetal RhD typing for targeted prophylaxis.
Hawk AF; Chang EY; Shields SM; Simpson KN
Obstet Gynecol; 2013 Sep; 122(3):579-85. PubMed ID: 23921866
[TBL] [Abstract][Full Text] [Related]
6. Fetal RHD genotyping in maternal serum during the first trimester of pregnancy.
Costa JM; Giovangrandi Y; Ernault P; Lohmann L; Nataf V; El Halali N; Gautier E
Br J Haematol; 2002 Oct; 119(1):255-60. PubMed ID: 12358932
[TBL] [Abstract][Full Text] [Related]
7. High-throughput, non-invasive prenatal testing for fetal Rhesus D genotype to guide antenatal prophylaxis with anti-D immunoglobulin: a cost-effectiveness analysis.
Saramago P; Yang H; Llewellyn A; Palmer S; Simmonds M; Griffin S
BJOG; 2018 Oct; 125(11):1414-1422. PubMed ID: 29415334
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and costs of non-invasive foetal RHD genotyping in rhesus-D negative mothers: a French multicentric two-arm study of 850 women.
Darlington M; Carbonne B; Mailloux A; Brossard Y; Levy-Mozziconacci A; Cortey A; Maoulida H; Simon T; Rousseau A; Durand-Zaleski I;
BMC Pregnancy Childbirth; 2018 Dec; 18(1):496. PubMed ID: 30547830
[TBL] [Abstract][Full Text] [Related]
9. [Non-invasive fetal RhD typing and RhD negative pregnant women--preliminary observations].
Guz K; Brojer E; Zupańska B; Orzińska A; Kalińska A; Bec JR
Ginekol Pol; 2004 Jan; 75(1):21-5. PubMed ID: 15112469
[TBL] [Abstract][Full Text] [Related]
10. Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study.
Finning K; Martin P; Summers J; Massey E; Poole G; Daniels G
BMJ; 2008 Apr; 336(7648):816-8. PubMed ID: 18390496
[TBL] [Abstract][Full Text] [Related]
11. A new fetal RHD genotyping test: costs and benefits of mass testing to target antenatal anti-D prophylaxis in England and Wales.
Szczepura A; Osipenko L; Freeman K
BMC Pregnancy Childbirth; 2011 Jan; 11():5. PubMed ID: 21244652
[TBL] [Abstract][Full Text] [Related]
12. Targeted antenatal anti-D prophylaxis program for RhD-negative pregnant women - outcome of the first two years of a national program in Finland.
Haimila K; Sulin K; Kuosmanen M; Sareneva I; Korhonen A; Natunen S; Tuimala J; Sainio S
Acta Obstet Gynecol Scand; 2017 Oct; 96(10):1228-1233. PubMed ID: 28718198
[TBL] [Abstract][Full Text] [Related]
13. Costs and benefits of non-invasive fetal RhD determination.
Teitelbaum L; Metcalfe A; Clarke G; Parboosingh JS; Wilson RD; Johnson JM
Ultrasound Obstet Gynecol; 2015 Jan; 45(1):84-8. PubMed ID: 25380024
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity of fetal RHD screening for safe guidance of targeted anti-D immunoglobulin prophylaxis: prospective cohort study of a nationwide programme in the Netherlands.
de Haas M; Thurik FF; van der Ploeg CP; Veldhuisen B; Hirschberg H; Soussan AA; Woortmeijer H; Abbink F; Page-Christiaens GC; Scheffer PG; Ellen van der Schoot C
BMJ; 2016 Nov; 355():i5789. PubMed ID: 27821701
[TBL] [Abstract][Full Text] [Related]
15. [Should the RhD prophylaxis be adjusted?].
Georgsen J; Sprogøe U
Ugeskr Laeger; 2004 Aug; 166(36):3072. PubMed ID: 15446237
[No Abstract] [Full Text] [Related]
16. Cost-effectiveness of first trimester non-invasive fetal RHD screening for targeted antenatal anti-D prophylaxis in RhD-negative pregnant women: a model-based analysis.
Neovius M; Tiblad E; Westgren M; Kublickas M; Neovius K; Wikman A
BJOG; 2016 Jul; 123(8):1337-46. PubMed ID: 26663771
[TBL] [Abstract][Full Text] [Related]
17. Fetal RHD genotyping is a cost-effective option for supporting targeted anti-D prophylaxis in D-negative pregnancies.
Allard S; Massey E
BJOG; 2018 Oct; 125(11):1423. PubMed ID: 29700947
[No Abstract] [Full Text] [Related]
18. Universal RHD genotyping in fetuses.
Kumar S
BMJ; 2008 Apr; 336(7648):783-4. PubMed ID: 18390495
[TBL] [Abstract][Full Text] [Related]
19. [Prevention of fetomaternal rhesus-D allo-immunization. Perspectives].
Cortey A; Brossard Y; Beliard R; Bourel D
J Gynecol Obstet Biol Reprod (Paris); 2006 Feb; 35(1 Suppl):1S119-1S122. PubMed ID: 16495837
[TBL] [Abstract][Full Text] [Related]
20. Detection of fetal RhD sequence from peripheral blood of sensitized RhD-negative pregnant women.
Lo YM; Noakes L; Bowell PJ; Fleming KA; Wainscoat JS
Br J Haematol; 1994 Jul; 87(3):658-60. PubMed ID: 7993816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
